Business Context and Reporting Period
This Form 8-K was filed by NantKwest, Inc. on April 16, 2018. The report discloses a corporate governance event regarding the departure of a director. Note: The request metadata references "Immunitybio, Inc.," but the filing text explicitly identifies the registrant as NantKwest, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
On April 16, 2018, John T. Potts, Jr., M.D., resigned from the Board of Directors effective immediately. The Company stated the resignation was for personal reasons and was not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the specific event of the director's resignation.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Dr. Potts' resignation.
- Confirm whether the resignation triggers any changes to committee assignments or quorum requirements.
- Review subsequent filings to determine if a replacement director was appointed.